SA
NBIX icon

Seneschal Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Seneschal Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338 Hold
2
– – ﹤0.01% 474
2026
Q1 		$264 Hold
2
– – ﹤0.01% 499
2025
Q4 		$284 Hold
2
– – ﹤0.01% 476
2025
Q3 		$281 Buy
+2
New +$271 ﹤0.01% 492

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Seneschal Advisors's NBIX Position: Q2 2026 in Review

Seneschal Advisors held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 2 shares worth $338. The position accounts for ﹤0.01% of the portfolio, ranked #474.

Seneschal Advisors first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Seneschal Advisors held 2 shares of Neurocrine Biosciences worth $338 as of Q2 2026.
  • Seneschal Advisors left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Seneschal Advisors's portfolio in Q2 2026, its #474 holding.
  • Seneschal Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.